What is RSV?
Respiratory syncytial virus (RSV) is a common respiratory virus that is increasingly present during the colder months, namely from the fall until the end of spring.
RSV is spread through contact with droplets projected by infected persons when they sneeze or cough as well as through direct contact with an infected surface. It usually presents with minor symptoms similar to those of the common cold, but can also develop into a severe illness of the airways (bronchiolitis) or the lungs (pneumonia). Complications from the illness can lead to hospitalization and even death.
Why should I protect my infant from this virus?
RSV is the primary cause of hospitalization of infants during their first year of life. Immunization remains the best way of protecting your child against RSV and any associated complications.
What does immunization against RSV entail?
Immunization against RSV consists of an injection of antibodies, administered during a single appointment as early as possible during the period, i.e., early fall, when the virus begins to manifest itself. The immunizing agent used for this purpose is Nirsevimab, an antibody that provides protection against RSV for a minimum of 5 months, roughly the length of the period during which the virus is present.
Who can receive Nirsevimab?
Immunization against RSV will be available as of this year in Québec, during the RSV season and for all newborns as well as children under 8 months of age. It is also recommended for some children aged 19 months or less who present with certain health conditions.
What are the known side effects?
The most frequent side effect subsequent to the administration of Nirsevimab is a rash (spots or red blotches on the skin). In certain cases, children could also develop a fever or a reaction at the injection site. These various reactions are not usually dangerous, but can prove uncomfortable.
Is the immunizing agent used safe?
The immunizing agent against RSV is indeed safe, as revealed in extensive studies conducted to prove both its safety and effectiveness.
How can Nirsevimab be obtained?
Nirsevimab will be offered to all newborns after their birth. You can also contact your CLSC or nursing station to inquire whether your child is eligible or to schedule an appointment.